"Newton001" The effects of tetrathiomolybdate, a donator of hydrogen sulphide, in animal models of brain ischemia

Lead Research Organisation: University College London
Department Name: Medicine

Abstract

Ischaemia (low oxygen) occurs when blood flow to a vital organ (e.g., heart, brain) is insufficient to meet metabolic demand. This leads to death of tissue and loss of function (i.e., as in heart attack, stroke). Presently, there are limited strategies to deal with ischaemia. Although reopening blood vessels (reperfusion) is a necessary, often lifesaving treatment that improves long-term outcome, 'reperfusion injury' upon restoration of blood supply can cause further damage. Attempts to decrease reperfusion injury have recently focussed on decreasing metabolism. For example, after cardiac arrest and resuscitation, decreasing body temperature (therapeutic hypothermia) may have a protective effect, although this takes time to initiate. Giving a drug that can decrease metabolism more rapidly could provide added benefit in this scenario. Hydrogen sulphide given either in gas form or intravenously could induce a state of 'suspended animation' in mice with marked reductions in core temperature and metabolic rate (Blackstone, Science 2005). However, this was far less effective in modulating metabolism in larger species, including rats. We made the novel discovery that the copper-modulating drug, tetrathiomolybdate (TTM), was a slow-releaser or hydrogen sulphide, and could safely induce suspended animation in rats, whereas native hydrogen sulphide had no effect, or toxicity at high doses. We previously found that, when used just prior to resuscitation in a severe haemorrhage-reperfusion injury rat model, mortality was halved. We also found benefit in a heart ischaemia-reperfusion model with a 43% reduction in damaged heart tissue. We wish to extend our findings to explore outcomes in animal models of brain ischaemia. We will focus on mechanisms associated with brain protection after TTM treatment, such as brain inflammation and cognitive performance.

Technical Summary

Brain ischaemia/reperfusion (BIR) occurs when blood flow to the brain is insufficient to meet metabolic demand. This leads to cerebral hypoxia and death of tissue. Mechanisms underlying post-ischaemic brain dysfunction vary however neuronal damage is often seen, resulting in loss of related functions. Hydrogen sulphide (H2S) given either in gas form or intravenously could induce a state of 'suspended animation' in mice, yet was far less effective in larger species, including rats. It acts by inhibition of mitochondrial respiration. We discovered that the copper chelator, ammonium tetrathiomolybdate (TTM) is a slow-acting sulfide donor with improved efficacy and safety in rats. Our recent cardiac ischaemia-reperfusion data shows a 43% reduction in infarct size. We hypothesize similar protection following BIR. Brain ischaemia will be induced focally or globally using well described models. Markers of brain inflammation and oxidative damage, brain temperature, mitochondrial function, and cognitive performance will be determined, as below:

Infarct volume: coronal sections of cerebrum will be stained with triphenyltetrazolium chloride solution and fixed with formaldehyde. The infarcted area will be analyzed using the Olympus Micro Image Lite 4.0 system.

Mitochondrial function: determined by ex vivo oxygen consumption, brain ATP content, measurement of mitochondrial membrane potential and ROS production.

Brain inflammation: determination of brain levels of TNF-alpha, IL-1beta, IL-6 and HMGB1 will be performed by commercially available ELISA kits.

Oxidative stress markers: measured by the ratio between oxidized and reduced glutathione, protein carbonyls, isoprostane, 4-hydroxynonenal and 3-nitrotyrosine levels.

Brain temperature: determined using a specific probe inserted into brain parenchyma.

Cognitive function: determined by the step-down inhibitory avoidance task.

Planned Impact

N/A
 
Title Therapeutic use of tetrathiomolybdate 
Description Repurposing of a drug for ischameia-reperfusion injury 
IP Reference WO 2011/121354 
Protection Patent granted
Year Protection Granted 2011
Licensed Commercial In Confidence
Impact Follow-on funding to further pursue development
 
Title Ammonium tetrathiomolybdate 
Description Repurposed drug for ischaemia-reperfusion injury. Shortly to undergo testing inp ig model (funded by Apollo Therapeuticcs) 
Type Therapeutic Intervention - Drug
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2018
Development Status Under active development/distribution
Impact None yet - under development